JP2019521098A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521098A5
JP2019521098A5 JP2018562357A JP2018562357A JP2019521098A5 JP 2019521098 A5 JP2019521098 A5 JP 2019521098A5 JP 2018562357 A JP2018562357 A JP 2018562357A JP 2018562357 A JP2018562357 A JP 2018562357A JP 2019521098 A5 JP2019521098 A5 JP 2019521098A5
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding fragment
complementarity determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018562357A
Other languages
English (en)
Japanese (ja)
Other versions
JP7162535B2 (ja
JP2019521098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/036818 external-priority patent/WO2017214548A1/en
Publication of JP2019521098A publication Critical patent/JP2019521098A/ja
Publication of JP2019521098A5 publication Critical patent/JP2019521098A5/ja
Priority to JP2022130091A priority Critical patent/JP2022159476A/ja
Application granted granted Critical
Publication of JP7162535B2 publication Critical patent/JP7162535B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018562357A 2016-06-10 2017-06-09 抗gitr抗体およびその使用 Active JP7162535B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022130091A JP2022159476A (ja) 2016-06-10 2022-08-17 抗gitr抗体およびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662348353P 2016-06-10 2016-06-10
US62/348,353 2016-06-10
US201662432023P 2016-12-09 2016-12-09
US62/432,023 2016-12-09
US201762500312P 2017-05-02 2017-05-02
US62/500,312 2017-05-02
PCT/US2017/036818 WO2017214548A1 (en) 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022130091A Division JP2022159476A (ja) 2016-06-10 2022-08-17 抗gitr抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2019521098A JP2019521098A (ja) 2019-07-25
JP2019521098A5 true JP2019521098A5 (https=) 2020-07-27
JP7162535B2 JP7162535B2 (ja) 2022-10-28

Family

ID=59078260

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018562357A Active JP7162535B2 (ja) 2016-06-10 2017-06-09 抗gitr抗体およびその使用
JP2022130091A Pending JP2022159476A (ja) 2016-06-10 2022-08-17 抗gitr抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022130091A Pending JP2022159476A (ja) 2016-06-10 2022-08-17 抗gitr抗体およびその使用

Country Status (19)

Country Link
US (3) US10738126B2 (https=)
EP (2) EP3468999B1 (https=)
JP (2) JP7162535B2 (https=)
KR (1) KR102495601B1 (https=)
CN (1) CN109563170B (https=)
AU (1) AU2017278193B9 (https=)
BR (1) BR112018075434A2 (https=)
CA (1) CA3027121A1 (https=)
CL (1) CL2018003515A1 (https=)
CO (1) CO2018013298A2 (https=)
IL (1) IL263273B2 (https=)
MA (1) MA45233A (https=)
MX (2) MX2018015350A (https=)
MY (1) MY200162A (https=)
PH (1) PH12018502502A1 (https=)
SG (1) SG11201810525XA (https=)
UA (1) UA128687C2 (https=)
WO (1) WO2017214548A1 (https=)
ZA (1) ZA201807920B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
CN109563170B (zh) 2016-06-10 2023-10-13 瑞泽恩制药公司 抗gitr抗体及其用途
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗lag-3抗体及びその使用方法
CN110168105B (zh) 2016-12-09 2024-05-24 瑞泽恩制药公司 用于对t细胞受体进行测序的系统和方法及其用途
US10752691B2 (en) * 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR20210126641A (ko) 2019-02-12 2021-10-20 리제너론 파아마슈티컬스, 인크. 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
WO2021136503A1 (en) * 2020-01-02 2021-07-08 Nanjing GenScript Biotech Co., Ltd. Anti-gitr antibodies and uses thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11787867B2 (en) * 2020-03-06 2023-10-17 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof
CN116761622A (zh) * 2021-01-08 2023-09-15 苏州丁孚靶点生物技术有限公司 药物产品及其用途
WO2022150654A2 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
EP4339209A4 (en) * 2021-05-10 2025-05-28 MediMabbio Inc. ANTI-GITR ANTIBODIES AND THEIR USES
IL314907A (en) 2022-03-15 2024-10-01 Yeda Res & Dev Antibodies against GITR and their uses

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2308787T3 (es) 1996-08-16 2008-12-01 Schering Corporation Antigenos de superficie de celular de mamiferos; reactivos relacionados.
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
WO1999025834A1 (en) 1997-11-18 1999-05-27 Genentech, Inc. Dna19355 polypeptide, a tumor necrosis factor homolog
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
US7618632B2 (en) 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
PT2343320T (pt) * 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
WO2007084775A2 (en) 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトil−6受容体に対する高親和性抗体
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-gitr 항체
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
WO2013051718A1 (ja) 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Th2 세포 전환용 에피토프 및 이의 용도
AR097306A1 (es) * 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
SI3148579T1 (sl) 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2808153T3 (es) * 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
CN109563170B (zh) 2016-06-10 2023-10-13 瑞泽恩制药公司 抗gitr抗体及其用途

Similar Documents

Publication Publication Date Title
JP2019521098A5 (https=)
JP7854529B2 (ja) 抗nkg2a抗体およびその使用
JP6866294B2 (ja) 抗pd−l1抗体
JP6839772B2 (ja) 抗PD−1抗体との組み合わせのための抗Tim−3抗体
JP6701213B2 (ja) 抗pd−1抗体
JP6518005B2 (ja) Pd−l1抗体
AU2014361473B2 (en) PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
JP2022510964A5 (https=)
JP2021531764A5 (https=)
JP2019521645A5 (https=)
CN110536903A (zh) 抗ox40抗体及其用途
JP2017535257A5 (https=)
JP2023543152A5 (https=)
RU2019134352A (ru) Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
JP2017532037A5 (https=)
JP2019500892A5 (https=)
JP2020515247A5 (https=)
AU2020283817A1 (en) TIGIT and PD-1/TIGIT-binding molecules
KR20160113272A (ko) Tim-3에 대한 항체 분자 및 그의 용도
JP2018501197A5 (https=)
IL299348B2 (en) Antigen-binding proteins against human papillomavirus and methods of using them
CN112334488B (zh) 靶向免疫检查点的双特异性抗体
WO2019030377A1 (en) CD96 BINDING AGENTS AS IMMUNOMODULATORS
JP2020504078A5 (https=)
JP2019528046A5 (https=)